Combining Docetaxel and Ifosfamide for Advanced Solid Tumors
Author Information
Author(s): LC Pronk, D Schrijvers, JHM Schellens, EA de Bruijn, ASTh Planting, D Locci-ToneIli, V Groult, J Verweij, AT van Oosterom
Primary Institution: Rotterdam Cancer Institute (Dr Daniel den Hoed Kliniek) and University Hospital Rotterdam
Hypothesis
Can the combination of docetaxel and ifosfamide be safely administered to patients with advanced solid tumors?
Conclusion
The combination of docetaxel and ifosfamide is feasible and shows some anti-tumor activity with manageable side effects.
Supporting Evidence
- Granulocytopenia grades 3 and 4 were observed in 89% of courses.
- One complete response and two partial responses were documented.
- The maximum tolerated dose was determined for both drug sequences.
- Febrile neutropenia occurred in 17% of courses.
- Non-haematological toxicities were mild to moderate.
Takeaway
Doctors tested two cancer drugs together to see if they work well and are safe for patients. They found that the combination can help some patients with cancer.
Methodology
Patients received either docetaxel followed by ifosfamide or vice versa, with dose escalation based on observed toxicities.
Limitations
The study was limited to a small sample size and focused only on the initial phase of drug combination testing.
Participant Demographics
{"age_range":"26-69","median_age":53,"gender_distribution":{"male":24,"female":10},"tumor_types":["Head and neck cancer","Non-small cell lung cancer","Malignant melanoma","Soft tissue sarcoma","Malignant mesothelioma","Primary unknown","Colon cancer","Miscellaneous"]}
Want to read the original?
Access the complete publication on the publisher's website